Biogen Shelves Alzheimer’s Drug Aduhelm, Shifts Focus to Leqembi
- February 02, 2024
Biogen Inc. will no longer sell the controversial Alzheimer’s drug Aduhelm and instead will focus its resources on another drug Leqembi® and other pipeline candidates for treating the disease, the company announced January 31.
ARTICLE TAGS
You must be logged in to access this content.